within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AC25_Cangrelor;

model Cangrelor
  extends Pharmacolibrary.Drugs.ATC.B.B01AC25;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>B01AC25</td></tr><td>route:</td><td>intravenous</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Cangrelor is a potent, reversible, intravenous P2Y12 platelet inhibitor used to prevent thrombotic events in patients undergoing percutaneous coronary intervention (PCI). It is approved for use in adults in the US and EU.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers; single and multiple intravenous bolus and infusion dosing.</p><h4>References</h4><ol><li><p>Gelbenegger, G, &amp; Jilma, B (2022). Clinical pharmacology of antiplatelet drugs. <i>Expert review of clinical pharmacology</i> 15(10) 1177–1197. DOI:<a href=&quot;https://doi.org/10.1080/17512433.2022.2121702&quot;>10.1080/17512433.2022.2121702</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36065676/&quot;>https://pubmed.ncbi.nlm.nih.gov/36065676</a></p></li><li><p>Bhattad, VB, et al., &amp; Khouzam, RN (2019). Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. <i>Annals of translational medicine</i> 7(17) 408–None. DOI:<a href=&quot;https://doi.org/10.21037/atm.2019.07.64&quot;>10.21037/atm.2019.07.64</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31660307/&quot;>https://pubmed.ncbi.nlm.nih.gov/31660307</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Cangrelor;
